Veterinary compound tulathromycin nanoemulsion and preparation method thereof

A telamycin and nanoemulsion technology, applied in the field of medicine, can solve the problems of reducing the efficacy of telamycin, inconvenient use of the suspension, and low bioavailability, so as to avoid the hepatic first-pass effect and emulsion The effect of good drop dispersion and simple preparation process

Inactive Publication Date: 2012-09-12
NORTHWEST A & F UNIV
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Tyramycin currently used for injection is a suspension, which is inconvenient to use, easy to block pinholes, low bioavailability, and poor absorption
There is also a method of dissolving telamycin in dilute acid for injection, which also faces two problems: 1) dilute ac

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Veterinary compound tulathromycin nanoemulsion and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

Embodiment 2

Embodiment 3

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Ld50aaaaaaaaaa
Login to view more

Abstract

The invention discloses veterinary compound tulathromycin nanoemulsion injection. Particle size of the nanoemulsion ranges from 1nm to 100nm and is made of the following raw materials in percentage by weight: 30%-40% of surfactant, 5%-15% of cosurfactant, 5%-15% of oil, 2%-5% of tulathromycin, 0.5%-1.25% of trimethoprim lactate, and the balance of deionized water. Bacteriostasis is achieved by administration of the injection once, and the bacteriostasis is quick and is slowly released. The nanoemulsion is capable of avoiding first pass effect of hepar and has neural pH so that animal stress reaction is reduced. The veterinary compound tulathromycin nanoemulsion injection is high in safety, simple to prepare and low in energy consumption, can be produced massively without special equipment, and has broad market prospect in the field of medicine.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a new dosage form of telamycin with antibacterial effect, in particular to a transparent and stable oil-in-water compound telamycin nanoemulsion injection and a preparation method thereof. Background technique Tulathromycin (Tulathromycin) is a newly marketed macrolide semi-synthetic antibiotic exclusively for animals. The Ministry of Agriculture of my country firstly allowed the use of telamycin in animal production in Announcement No. 957 in 2008. Tyramycin is a broad-spectrum antibacterial drug, which is effective against pathogenic bacteria that cause respiratory diseases in pigs and cattle, such as Pasteurella hemolyticus, Pasteurella multocida, Haemophilus somnus, Mycoplasma, Actinobacillus pleuropneumoniae, bronchial septicemia Bordetella, Haemophilus parasuis, etc., and Moraxella bovis, which causes bovine infectious keratoconjunctivitis, are particularly sensitive. It has many ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7052A61K31/505A61K9/107A61K47/34A61K47/14A61K47/08A61P31/04A61P11/00A61P27/02
Inventor 欧阳五庆周莹欧阳伸雨
Owner NORTHWEST A & F UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products